In-Depth Market Analysis On Carbonic Anhydrase 9 - Pipeline Review, H1 2016

​Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Carbonic Anhydrase 9 - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1)
- The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 

Reasons to buy

- Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1)
- Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Advaxis, Inc. Akshaya Bio Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###